Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China · Delayed Price · Currency is CNY 48.78
+0.79 (1.65%)
At close: Aug 4, 2026
SHA:688193 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,892 | 1,876 | 1,384 | 1,805 | 1,869 | - | |
Market Cap Growth | -8.36% | 35.55% | -23.33% | -3.43% | - | - |
Enterprise Value | 1,109 | 1,097 | 711 | 1,000 | 1,043 | - |
Last Close Price | 48.78 | 47.46 | 34.88 | 43.57 | 44.98 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 137.35 | 185.95 | - | 218.52 | 80.10 | - |
PS Ratio | 11.58 | 11.58 | 7.80 | 10.98 | 6.15 | - |
PB Ratio | 2.06 | 2.05 | 1.52 | 1.88 | 1.94 | - |
P/TBV Ratio | 2.06 | 2.05 | 1.52 | 1.88 | 1.95 | - |
P/FCF Ratio | 218.68 | 122.34 | 99.82 | - | - | - |
P/OCF Ratio | 125.06 | 83.71 | 56.74 | 104.98 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.79 | 6.77 | 4.01 | 6.08 | 3.43 | - |
EV/EBITDA Ratio | 70.27 | 135.45 | - | - | 59.85 | - |
EV/EBIT Ratio | - | - | - | - | 207.76 | - |
EV/FCF Ratio | 128.22 | 71.52 | 51.28 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.32 | 0.56 | - | - | 0.54 | 0.05 |
Debt / FCF Ratio | 0.58 | 0.40 | 0.31 | - | - | 0.14 |
Net Debt / Equity Ratio | -0.85 | -0.89 | -0.87 | -0.81 | -0.85 | -0.67 |
Net Debt / EBITDA Ratio | -59.83 | -100.60 | 38.23 | 57.94 | -47.04 | -2.73 |
Net Debt / FCF Ratio | -90.46 | -53.12 | -57.53 | 243.43 | 32.38 | -6.93 |
Asset Turnover | 0.17 | 0.16 | 0.17 | 0.15 | 0.41 | 0.85 |
Inventory Turnover | 1.72 | 1.62 | 1.46 | 1.13 | 4.45 | 4.16 |
Quick Ratio | 14.10 | 12.58 | 11.47 | 11.06 | 9.83 | 3.89 |
Current Ratio | 14.97 | 12.91 | 11.89 | 11.46 | 10.19 | 4.26 |
Return on Equity (ROE) | 1.51% | 1.10% | -0.83% | 0.86% | 3.74% | 25.70% |
Return on Assets (ROA) | -0.01% | -0.34% | -2.13% | -1.53% | 0.43% | 11.35% |
Return on Invested Capital (ROIC) | -0.19% | -4.97% | -23.42% | -16.08% | 3.72% | 79.35% |
Return on Capital Employed (ROCE) | 0.00% | -0.60% | -3.80% | -2.70% | 0.50% | 20.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.73% | 0.54% | -0.56% | 0.46% | 1.25% | - |
FCF Yield | 0.46% | 0.82% | 1.00% | -0.18% | -1.35% | - |
Dividend Yield | 2.40% | 2.42% | 0.57% | 0.46% | 0.28% | - |
Payout Ratio | 69.89% | 96.04% | - | 60.54% | - | 0.08% |
Buyback Yield / Dilution | -0.21% | 0.67% | 0.68% | -2.83% | -26.08% | -0.95% |
Total Shareholder Return | 2.37% | 3.10% | 1.26% | -2.37% | -25.80% | -0.95% |